Thyroid medication recalled after Chinese supplier fails inspection

pharmafile | August 20, 2018 | News story | Sales and Marketing China, FDA, recall, thyroid, westminster 

The Mississippi based manufacturer Westminster Pharmaceuticals is voluntarily recalling thyroid medications Levothyroxine and Liothyronine after the Chinese company Sichuan Friendly Pharmaceutical Co failed an FDA inspection.

Sichuan Pharmaceutical who supplied Westminster with an Active Pharmaceutical Ingredient (API) used in the production of certain thyroid medications were found to have deficiencies with Current Good Manufacturing Practices (cGMP) and thus could pose a risk to patient safety.

As of yet there have been no reported adverse events in relation to the medications. The fda warned that “Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product.”

Westminster has told its wholesalers to immediately stop distributing the medications involved while also making arrangements for already distributed products to be returned.

The recall comes as drug safety scandals have plagued Chinese manufacturers in recent months. While protests erupted in Beijing over Changsheng Biotechnology’s corrupt practices, regulators recalled Chinese produced valsartan after it was found that some batches may be contaminated with carcinogens.

Louis Goss

Related Content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …

Biogen’s biosimilar Tofidence approved by FDA

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …


Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the …

Latest content